PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gastaldelli, A.* ; Stefan, N. ; Häring, H.-U.

Liver-targeting drugs and their effect on blood glucose and hepatic lipids.

Diabetologia 64, 1461-1479 (2021)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium-glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
10.122
2.542
4
10
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Farnesoid X Receptor Agonists ; Fibrosis ; Hepatokines ; Incretins ; Insulin Resistance ; Non-alcoholic Fatty Liver Disease ; Non-alcoholic Steatohepatitis ; Peroxisome Proliferator-activated Receptor (ppar) Agonists ; Review ; Sglt2 Inhibitors; Type-2 Diabetes-mellitus; Improves Insulin Sensitivity; Cotransporter 2 Inhibitor; Glucagon-like Peptide-1; X-receptor Agonist; Placebo-controlled Trial; Tyrosine-phosphatase 1b; Fatty Liver; Nonalcoholic Steatohepatitis; Double-blind
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Zeitschrift Diabetologia
Quellenangaben Band: 64, Heft: 7, Seiten: 1461-1479 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
POF Topic(s) 90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502400-001
Förderungen Consiglio Nazionale delle Ricerche
DOI 10.1007/s00125-021-05442-2
WOS ID WOS:000641662300001
Scopus ID 85104996942
PubMed ID 33877366
Erfassungsdatum 2021-05-28
[➜Korrektur melden]